Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q2 2022 vs. Q1 2022
How the institutions holding Aligos Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 76 | 3 | 60 | −13 |
| Shares | 31.8M | 213.3K | 29.8M | −1.81M (−5.7%) |
| Value | $68.4M | $458.0K | $36.0M | −$31.9M (−47.0%) |
3 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tang Capital Management LLC | 1,547,710 | $1.87M | 0.28% |
| Newtyn Management, LLC | 962,088 | $1.16M | 0.22% |
| Millennium Management LLC | 464,409 | $562.0K | 0.00% |
| New York Life Investment Management LLC | 216,902 | $262.0K | 0.00% |
| Ergoteles LLC | 103,700 | $125.0K | 0.00% |
| Bridgeway Capital Management, LLC | 57,000 | $69.0K | 0.00% |
| AQR Capital Management LLC | 48,045 | $58.0K | 0.00% |
| Oasis Management Co Ltd. | 45,797 | $55.0K | 0.01% |
| Brinker Capital Investments, LLC | 44,649 | $54.0K | 0.00% |
| Tri Locum Partners LP | 29,302 | $35.0K | 0.01% |
| Atom Investors LP | 22,685 | $27.0K | 0.01% |
| Gsa Capital Partners LLP | 20,718 | $25.0K | 0.00% |
| Wedmont Private Capital | 20,741 | $25.0K | 0.01% |
| Qube Research & Technologies Ltd | 18,689 | $23.0K | 0.00% |
| Susquehanna International Group, LLP | 16,036 | $19.0K | 0.00% |
| Capital Advisors, Ltd. LLC | 887 | $1.00K | 0.00% |
Sold out (29)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
Not filed for Q2 2022 yet (3)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| IndexIQ Advisors LLC | 192,976 | $415.0K |
| Golden State Wealth Management, LLC | 16,860 | $36.0K |
| Amalgamated Financial Corp. | 3,439 | $7.00K |